This prospective, multicenter cohort study will recruit eligible HPV16/18-positive women from three tertiary hospitals in China. Peripheral blood samples and clinical data (cytology, HPV genotyping, colposcopy-directed biopsy) will be collected, followed by standardized mass cytometry (CyTOF) to develop and evaluate an immune model across cervical lesion grades.
Availability of cervical cytology results
Consent to colposcopy and cervical biopsy
Signed informed consent
Confirmed diagnosis of CIN2 or worse
Prior cervical ablation, cervical conization, chemoradiotherapy, or immunotherapy
Other malignancy within the past 2 years not in complete remission
Presence of other systemic immune disease or active infection
Women's Hospital School Of Medicine Zhejiang University
Lead sponsor
Jiaxing Maternity and Child Health Care Hospital
Collaborator
Ningbo Women & Children's Hospital
Collaborator
Zhejiang PuLuoTing Health Technology Co., Ltd.
Collaborator